<DOC>
	<DOC>NCT00115206</DOC>
	<brief_summary>The purpose of this study is to estimate the relationship between patient reported outcomes (PROs) and neutropenia (or its complications) in NSCLC subjects receiving chemotherapy with or without Neulasta® (pegfilgrastim).</brief_summary>
	<brief_title>Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Nonsmall cell lung cancer, not previously treated with chemotherapy or radiotherapy ECOG performance status 0 or 1 ANC greater than or equal to 2.0 x 10^9/L Cancer other than NSCLC within 5 years of enrollment, with the exception of surgically cured basal cell carcinoma or in situ carcinoma of the cervix Treatment less than or equal to 30 days prior with any experimental agent Subjects with symptomatic brain metastases Subject is currently enrolled or has not yet completed at least 30 days since ending other investigational device or drug trial(s) or is receiving other investigational agent(s)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Fever</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Neulasta®</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Amgen</keyword>
</DOC>